使用多层API涂层技术开发蒙特卢卡斯特和利沃二化的稳定固定剂量组合
Dong-Joon Oh1, Seo-Young Shin2, Chae-Yong Lim2
1Han Wha Pharma Co., Ltd., Gyeonggi Bio Center 14F, 147, Gwanggyo-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16229, South Korea; Yonsei Institute of Pharmaceutical Sciences & College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, South Korea.
International journal of pharmaceutics
|March 28, 2025
概括
这项研究开发了一种使用多层API涂层技术 (M-LAC Tech) 的新型组合药片,用于蒙特卢卡斯特和利沃二化物. M-LAC Tech配方增强了稳定性,并使药物顺序释放成为可能,改善了患者的治疗结果.
科学领域:
- 制药技术 制药技术 制药技术
- 药物输送系统 药物输送系统
- 药用化学 医学化学
背景情况:
- 传统的组合疗法经常面临药物相互作用和稳定性的挑战.
- 为多种活性药物成分 (API) 开发单剂型需要先进的配方策略.
- 蒙特卢卡斯特和莱沃二二化物通常一起用于过敏症.
研究的目的:
- 开发一个稳定的组合药物产品的蒙特卢卡斯特和莱沃二化物.
- 利用多层API涂层技术 (M-LAC技术) 进行连续的药物释放,并防止化学相互作用.
- 通过优化剂型来增强药理动力学特征和患者的服药性.
主要方法:
- 准备一个核心的蒙特卢卡斯特片,然后再进行屏障涂层.
- 使用M-LAC技术在屏障层上涂抹Levosetirizine二化物作为药物涂层的应用.
- 添加一个外部保护层,以创建一个多层的薄膜涂层药片.
主要成果:
- 与双层平板相比,M-LAC Tech平板实现了50%的尺寸缩小,改善了患者的服药性.
- 屏障涂层证实了药物相互作用的有效预防和增强的稳定性.
- 连续释放药物导致AUC变异性降低,Tmax缩短,与同时释放配方相比,药物动力学特性优越.
结论:
- M-LAC Tech成功地使两个API稳定地纳入到一个单一的剂量形式.
- 该技术通过防止药物相互作用和优化释放配置文件,提供了显著的临床优势.
- 这一进步为未来的组合药物开发提供了潜力,提供更小的剂量形式和更好的疗效.
相关概念视频
01:01Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222